Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The LC-MS/MS-based diagnostics market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.
The LC-MS/MS-based diagnostics market is expanding quickly due to the many advantages that these technologies provide over conventional immunoassays, and ongoing developments in these technologies are encouraging their use even more. Additionally, the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) as a routine diagnostic tool has increased. Due to its unmatched analytical benefits, such as outstanding specificity, sensitivity, and multiplex testing capabilities-ualities that are essential for intricate diagnostic tasks LC-MS/MS is becoming more and more popular in the diagnostics industry.
A vital analytical technique that combines the precise mass analysis of mass spectrometry with the separation capabilities of liquid chromatography is called liquid chromatography-mass spectrometry (LC-MS). This collaboration makes it possible to analyze complex mixtures in detail, which facilitates the identification and measurement of molecules across a range of sectors. In the pharmaceutical business, LC-MS is crucial to the drug development process, from assessing drug metabolism and pharmacokinetics to ensuring quality control. LC-MS is crucial in clinical diagnostics to assess biomarkers and help disease diagnosis and monitoring.
Researchers are becoming more interested in machine learning as a formidable tool for data processing and pattern recognition because of its potential application in non-targeted research. Artificial intelligence (AI) and liquid chromatography-mass spectrometry (LC-MS) technologies are being employed quickly to enhance data processing, method development, and even automated instrument control, among other research fields. The use of AI techniques, particularly machine learning, is leading to better peak recognition, less manual data interpretation, and the identification of correlations between chemical properties and chromatographic performance.
High Demand for Advanced Analytical Tools
The increasing reliance on advanced quantitative analytic methods for diagnosis is one of the primary drivers of the LC-MS/MS-based diagnostics market. Medical professionals can choose the best therapies by using these tools to assist them in making an accurate diagnosis. This demand is also being driven by the increasing prevalence of chronic diseases and the need for precision therapy, which depends on accurate molecular analysis.
Complexity in Parameter Optimization
While creating LC-MS/MS analytical techniques for biological matrix analysis, a number of factors, such as chromatography, extraction, and instrument-specific parameters, need to be tuned. In addition to increasing the uncertainty of assay findings, impurities on the analytical column might result in excessive system backpressure, background noise related to the gradient and flow, changing retention durations, and irregular peak shape.
Personalized Medicine Demand
The LC-MS/MS-based diagnostics market has a lot of prospects due to the rising trend toward customized healthcare. In 2024, 72% of the more than 2.2 million personalized treatment tests performed worldwide used LC-MS methods for metabolic and genetic profiling. In partnership with biotech companies, more than 120 novel LC-MS-based methods were introduced as part of companion diagnostics development. The number of hospitals using LC-MS machines for personalized medication monitoring increased by 18% to 2,400 establishments.
North America dominated the LC-MS/MS-based diagnostics market in 2024. North America has a strong healthcare system, which is the main driver of increased growth. When it comes to developing new drugs and introducing treatments for uncommon and deadly medical ailments, the nation is renowned for its forward-thinking attitude. More money is being spent on environmental testing as a result of the government's tougher stance on environmental pollution. The nation's healthcare spending is enormous.
In the U.S., the National Health Expenditure Accounts (NHEA) give the official estimates of the total amount spent on health care. The cost of health care in the U.S. rose by 7.5 percent to $4.9 trillion, or $14,570 per person, in 2023. In the nation, health care accounted for around 17.6 percent of GDP.
Canada has had a general increase in healthcare spending over the last five years, partly due to population growth and the growing cost of medical services and technology. An increasing population has led to an expansion of the healthcare system, which has increased overall spending. This rise shows that all Canadians will have access to healthcare services. Between 2023 and 2025, the pattern reversed once more, with healthcare spending rising relative to Canada's GDP. This comeback suggests that healthcare investment is being prioritized again or that economic growth is slowing down in comparison to healthcare spending.
Asia Pacific is estimated to host the fastest-growing LC-MS/MS-based diagnostics market during the forecast period. Because the pharmaceutical industry is growing, healthcare demands are increasing, and government research spending is increasing. China, India, Japan, and South Korea are among the nations driving this trend, aided by encouraging policies and expanding infrastructure. LC-MS is being used for environmental testing, medication discovery, and medical trials in the region's thriving biotechnology and educational sectors. Additionally, the haste with which environmental tracking and meal checking out are being modernized throughout Asia opens up new opportunities for LC-MS manufacturers. It is expected that the use of LC-MS will rise significantly as awareness of analytical precision and precise manipulation increases.
By 2037, China's senior population (those aged 60 and above) would number 355 million, a net increase of 91 million over the 264 million at the end of 2022. Healthcare expenses increase as people get older. In addition to pursuing cost-effectiveness, hospitals are committed to increasing productivity via the use of advanced technologies. This can significantly improve the overall efficacy of the therapy cycle.
The Ministry of Health and Family Welfare (MoHFW) has recommended that states increase health spending by at least 10% annually and give the health sector first priority. On December 10, 2024, 1,75,418 Ayushman Arogya Mandirs (AAMs) were created and opened via the conversion of existing Sub-Health Centers (SHCs) and Primary Health Centers (PHCs) in both urban and rural regions. AAMs seek to broaden the breadth of universal, free, and community-based primary healthcare services, in addition to preventative, promotive, curative, palliative, and rehabilitative treatments encompassing reproductive and child care services, infectious and non-communicable illnesses, and all health conditions.
Europe is expected to grow significantly in the LC-MS/MS-based diagnostics market during the forecast period. The European market is expanding rapidly due to the stringent regulations controlling pharmaceuticals, food safety, and environmental monitoring. In terms of geography, countries such as Germany, the United Kingdom, and France are leading the way in the deployment of mass spectrometry systems. The effect of hospitals and research laboratories, together with the necessity for accurate diagnosis and customized therapy, is driving the growth of the European market.
By the end of 2023, there were 845 microbiologists and 1,206 laboratory medicine physicians practicing in Germany, according to the German Medical Association's medical register. Furthermore, Germany is where a sizable portion of the in vitro diagnostics manufacturing is done. This sector comprises several small and medium-sized businesses in addition to major corporations like Roche Diagnostics, Siemens, Abbott, and Beckman Coulter. Germany has the highest IVD industry involvement in the EU.
Initial estimates indicate that nominal healthcare spending in the United Kingdom was about £317 billion in 2024. The UK government, which finances the majority of healthcare expenditures, spent £258 billion in 2024, a 2.5% real increase from 2023. The largest non-government financing source in 2024 was out-of-pocket spending, which includes consumer spending on hospital treatments, medical supplies, and other health services, as well as certain long-term care services. Out-of-pocket costs accounted for £46 billion, or 14.6%, of all healthcare expenditures in 2024.
In January 2025, according to Juergen Srega, President of the Bruker CALID Group, "Our strategic partnership with RECIPE is a critical step to democratize quick, effective, and sensitive assays for TDM, drugs of abuse screening, and other clinical assays on a high-throughput, chrom-free TQ-MS platform," given the growing importance of triple-quadrupole-based small molecule clinical diagnostics. (Source - Businesswire)
By Region
June 2025
June 2025
June 2025
June 2025